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Cardiac arrhythmias are a major cause of morbidity and mortality. In younger patients,
the majority of sudden cardiac deaths have an underlying Mendelian genetic cause.
Over the last 15 years, enormous progress has been made in identifying the distinct
clinical phenotypes and in studying the basic cellular and genetic mechanisms associated
with the primary Mendelian (monogenic) arrhythmia syndromes. Investigation of the
electrophysiological consequences of an ion channel mutation is ideally done in the
native cardiomyocyte (CM) environment. However, the majority of such studies so far
have relied on heterologous expression systems in which single ion channel genes are
expressed in non-cardiac cells. In some cases, transgenic mouse models have been
generated, but these also have significant shortcomings, primarily related to species
differences. The discovery that somatic cells can be reprogrammed to pluripotency as
induced pluripotent stem cells (iPSC) has generated much interest since it presents an
opportunity to generate patient- and disease-specific cell lines from which normal and
diseased human CMs can be obtained These genetically diverse human model systems
can be studied in vitro and used to decipher mechanisms of disease and identify strategies
and reagents for new therapies. Here, we review the present state of the art with respect
to cardiac disease models already generated using IPSC technology and which have been
(partially) characterized. Human iPSC (hiPSC) models have been described for the cardiac
arrhythmia syndromes, including LQT1, LQT2, LQT3-Brugada Syndrome, LQT8/Timothy
syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT). In most
cases, the hiPSC-derived cardiomyoctes recapitulate the disease phenotype and have
already provided opportunities for novel insight into cardiac pathophysiology. It is expected
that the lines will be useful in the development of pharmacological agents for the
management of these disorders.
Keywords: induced pluripotent stem cells, cardiac arrhythmia syndromes, electrophysiology, cardiomyocytes,
human, iPS, heart
INTRODUCTION
Cardiac arrhythmias can be life threatening and are a major
cause of morbidity and mortality in developed nations (Wolf and
Berul, 2008). In older patients, most arrhythmic sudden deaths
occur in the setting of acute ischemia or coronary artery dis-
eases (Zipes and Wellens, 1998). In younger patients, the great
majority of sudden arrhythmic deaths have an underlying genetic
cause (Wilde and Bezzina, 2005). These can be broadly subdi-
vided into those associated with structural heart disease (such
as hypertrophic cardiomyopathy) and those associated with elec-
trical disease in the structurally normal heart (Wolf and Berul,
2008).
Over the last 15 years, much progress has been made in
identifying the clinical phenotypes and cellular and genetic mech-
anisms underlying the various primary Mendelian arrhythmia
syndromes, including the Long QT syndrome (LQTS), Brugada
Syndrome (BrS), and catecholaminergic polymorphic ventric-
ular tachycardia (CPVT) (Wilde and Bezzina, 2005). This has
provided important insights into these disorders and as a con-
sequence improved the management of affected patients. The
availability of genetic tests has added an important diagnostic
tool permitting early (presymptomatic) identification of patients
at risk and allowing for the timely implementation of preven-
tive strategies (Hofman et al., 2010). Studies into genotype–
phenotype relationships have uncovered important gene-specific
aspects of disease and indicated that patient management must
take the nature of the gene affected into consideration (Priori,
2004). However, there is considerable variation in phenotypic
expression of arrhythmia syndromes even within families carry-
ing the same mutation (Scicluna et al., 2008).
Studying the electrophysiological andmolecular consequences
of a mutation associated with cardiac arrhythmia is ideally
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done in the native cardiomyocyte (CM) environment. However,
obtaining ventricular cardiac biopsies from patients is a highly
invasive procedure and not without significant risk. Consequently
themajority of functional studies on specificmutations associated
with the Mendelian rhythm disorders have relied on heterologous
expression systems, primarily Xenopus oocytes, human embry-
onic kidney (HEK) cells, and Chinese Hamster Ovary (CHO)
cells (Watanabe et al., 2008), in which the mutated ion chan-
nel of interest is expressed. Such cellular models have significant
shortcomings since they lack important constituents of cardiac
ion channel macromolecular complexes that might be required
to reproduce the exact molecular and electrophysiological phe-
notype of the mutation. For example, the behavior of the Na+
channel in cell expression systems seems to be different from
that in CMs (Remme et al., 2008). One way of overcoming this
has been to generate transgenic mice carrying specific muta-
tions (Sabir et al., 2008). However, the generation of such mouse
models is costly and time-consuming and not practical for high-
throughput screening of rare inherited arrhythmia mutations.
Moreover, there remain crucial differences between mouse and
human cardiac electrophysiological characteristics, such as the
high basal heart rate (>500 bpm), the very negative action poten-
tial (AP) plateau phase, and the short AP compared of the mouse
compared to human (Watanabe et al., 2011). These differences are
amongst others due to the different biophysical properties in the
transient outward currents (Ito) of human andmouse (for review,
see Nerbonne and Kass, 2005).
The discovery of somatic cell reprogramming to generate
induced pluripotent stem cells (iPSC) (Takahashi and Yamanaka,
2006) has created much excitement because of the possibility
of producing unique patient- and disease-specific human iPSC
(hiPSC) lines (Takahashi and Yamanaka, 2006; Takahashi et al.,
2007; Yu et al., 2007). With this technique, somatic cells can be
turned into embryonic stem cell-like cells which can differentiate
into all cells of the human body and be propagated indefinitely
in culture. Thus, hiPSC can provide investigators with genetically
diverse humanmodel systems to study mechanisms of disease and
identify strategies for potential new therapies. Zhang et al. (2009)
were the first to show that hiPSC can differentiate to functional
CMs, making it possible to generate patient-specific human CMs
which are by definition on different genetic backgrounds. hiPSC-
derived CMs (hiPSC-CMs) therefore represent a new model
system for studying Mendelian arrhythmia syndromes.
Here we provide a short overview of hiPSC generation, cultur-
ing, and differentiation methods. Further we will discuss in detail
the electrophysiological characteristics of hiPSC-CMs and review
hiPSCmodels for cardiovascular diseases, including LQT1, LQT2,
LQT3/BrS, LQT8/Timothy syndrome, and CPVT.
DERIVATION OF hiPSC MODELS
CELL ORIGIN
Although the first hiPSC lines were derived from dermal fibrob-
lasts (Takahashi et al., 2007) hiPSC can now be generated from
a wide variety of somatic cells. It is important to consider eas-
ily accessible sources, which are efficient to reprogram and give
minimal burden to the patient. Easily accessible sources used suc-
cessfully for reprogramming include keratinocytes from skin or
plucked hair (Aasen et al., 2008), peripheral blood (Loh et al.,
2009), mesenchymal cells in fat (Sun et al., 2009), dental pulp
(Tamaoki et al., 2010), and oral mucosa (Miyoshi et al., 2010).
CELL REPROGRAMMING
Somatic cells can be reprogrammed to a pluripotent state
by introducing pluripotency-associated genes. The first iPSC
reported were generated by transducing mouse fibroblasts
with four retroviral vectors OCT4, SOX2, KLF4, and C-MYC
(Takahashi and Yamanaka, 2006). The first hiPSC were generated
using the same four retroviral vectors (Takahashi et al., 2007) or
OCT4, SOX2, LIN28, and NANOG (Yu et al., 2007). Later studies
reported reprogramming with other combinations and numbers
of pluripotency factors. The hiPSC thus generated can be kept
in culture indefinitely using a variety of undefined fibroblast
feeder cells and fetal calf serum-based methods (Takahashi et al.,
2007; Yu et al., 2007) or defined mTESr/Matrigel-based proto-
cols. Transplantation of hiPSC into immune-compromised mice
leads to the formation of teratomas with derivatives of the three
embryonic germ layers, demonstrating the pluripotent potential
of these cells (Takahashi et al., 2007; Yu et al., 2007). In addition,
differentiation of hiPSC in vitro also results in derivatives of the
three germ layers. The review by Narsinh et al. (2011) provides
a detailed overview of the methods to reprogram somatic cells
to iPSC and discusses the advantages and disadvantages of the
different techniques.
GENERATION OF iPSC-DERIVED CARDIOMYOCYTES
When iPSC are removed from differentiation suppression con-
ditions and/or when grown in suspension aggregates [called
embryoid bodies (EBs)] spontaneous differentiation to cells of
the three germ layers occurs. CMs originate from the mesoder-
mal germ layer, so that CM differentiation first requires efficient
differentiation toward the mesodermal lineage. Directed differ-
entiation toward the cardiac lineage is mainly achieved by one
of the following strategies: (1) The first involves the formation
of EBs in the presence of growth factors and repressors known
to influence heart development (Kehat et al., 2001); (2) The
second relies on the influence of endoderm on cardiac differ-
entiation during embryogenesis (Mummery et al., 2003). Here,
co-culture of iPSC with mouse END-2 is used to produce CMs;
(3) The third involves monolayer culture at high density of iPSC
seeded on Matrigel with sequential treatment with activin A and
BMP4 (Laflamme et al., 2007). This method was developed using
human embryonic stem cells (hESC) but has been transferred to
hiPSC. Beating areas from differentiated EBs usually appear in
7–10 days. These EBs can be microscopically dissected and dis-
sociated in single cells. For electrophysiological and immunoflu-
orescence analysis, the dissociated cells can be seeded onto glass
coverslips.
CHARACTERISTICS OF hiPSC-DERIVED
CARDIOMYOCYTES
MOLECULAR AND STRUCTURAL CHARACTERISTICS
The first hiPS-CMs were generated by Zhang et al. (2009). In
these cells the investigators examined the gene expression of the
transcription factor Nkx2.5, the myofilament proteins cardiac
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troponin T, α-myosin heavy chain, α-actinin, the atrial and ven-
tricular isoforms of myosin light chain 2, atrial natriuretic factor,
and phospholamban (PLN). Low levels of cardiac troponin T
and the atrial isoform of myosin light chain 2 were found in
undifferentiated hiPSC and high expression of all the cardiac
genes were found in the hiPSC-CMs, which was comparable to
the expression of these genes in adult ventricular myocardium.
Immunohistochemistry showed a typically striated pattern for
α-actinin and myosin light chain. However, these cells had multi-
angular morphologies and relatively disorganized sacromeres
(Dick et al., 2010). Novak and co-workers demonstrated by trans-
mission electron microscopy analysis that hiPSC-CM had an
immature ultra structure without t-tubuli (Novak et al., 2012).
ACTION POTENTIALS
Using the patch clamp technique, Zhang et al. (2009) were the first
to measure the APs in spontaneously contracting cells isolated
from hiPSC-EBs. Themajority of the cells showed ventricular-like
APs (70–74% of cells for two distinct hiPSC lines), but atrial-like
and nodal-like APs were also observed. The distinction was made
on AP phenotype, with a negative diastolic membrane potential,
a rapid AP upstroke and a long plateau phase for ventricular-
like APs. The absence of a prominent plateau phase was a
characteristic of atrial-like APs, resulting in shorter AP dura-
tion compared to ventricular-like APs. Nodal-like APs showed a
more positive maximum diastolic potential (MDP), a slower AP
upstroke and a prominent phase 4 depolarization. Other studies
also described ventricular-like, atrial-like, and sometimes nodal-
like APs (Moretti et al., 2010; Fatima et al., 2011; Itzhaki et al.,
2011a; Ma et al., 2011; Matsa et al., 2011; Jung et al., 2012; Lahti
et al., 2012), with the ventricular-like phenotype being the most
prominent AP form (76–48%) (Zhang et al., 2009; Moretti et al.,
2010; Itzhaki et al., 2011a; Ma et al., 2011; Lahti et al., 2012).
Comparison of hiPSC-CMs to hESC-CMs seems valuable, since
hESC-CMs are more established. In hESC-CM, ventricular-like
APs are also observed more frequently [50–60% (Zhang et al.,
2009, 2011)]. Moretti et al. (2010) employed single-cell reverse-
transcriptase-PCR in combination with patch-clamp in the same
cell to show that the designation as ventricular-like, atrial-like,
and nodal-like APs based on cellular electrophysiological fea-
tures correlated with gene-expression of specific myocyte-lineage
markers.
Table 1 summarizes the reported AP characteristics of hiPSC-
CMs, hESC-CMs, and native ventricular CMs. The APs measured
in hiPSC-CM differ from APs measured in freshly isolated native
CMs (Table 1). The first remarkable difference is that most of the
hiPSC-CMs studied, including the ventricular-like and atrial-like
cells, are spontaneously active, with beating rates between 28 and
108 bpm (Table 1). Whether, in these studies, the spontaneous
activity was used as a tool for CM selection and that non-beating
CMs were also present, or whether it is a typical feature of
hiPSC-CMs is unknown. We recently (Davis et al., 2012) per-
formed experiments on non-spontaneously beating hiPSC-CM.
For this we selected quiescent cells which were able to contract
upon field stimulation. In these non-spontaneous beating hiPSC-
CM, the resting membrane potential (RMP) was more negative
then the MDP in most studies reporting on spontaneously active
hiPSC-CMs (Table 1). Compared with native human ventricu-
lar CMs, where the reported RMP varies from –81.8 to –87mV
(Table 1), the MDP of ventricular-like hiPSC-CM APs is less
negative with values ranging from –57 to –75mV (Table 1). In
spontaneously beating hiPSC-CM, the ventricular-like AP has a
maximal upstroke velocity (dV/dtmax) ranging from 9 to 40V/s
which is slow compared to those non-spontaneously beating
hiPSC-CM with a dV/dtmax of 115V/s, and native ventricu-
lar CMs with a dV/dtmax of 215–234 V/s (Magyar et al., 2000).
Table 1 | Action potential characteristics in hiPSC-CM and human ventricular cardiomyocytes.
Cell type BPM APD90 dv/dtmax APA MDP/RMP Exp. conditions References
(ms) (V/s) (mV) (mV)
iPSC-CM V IMR90C4 43.8±2.7 320.1±17 40.5± 4.6 87.7± 2.6 −63.5±1.7 37◦C, me LJP: corr. Zhang et al., 2009
iPSC-CM V ForeskinC1 44.2±3.5 312.5±11.2 27.2± 3.7 87.9± 2.4 −63.3±1.5 37◦C, me LJP: corr. Zhang et al., 2009
iPSC-CM V 68.2±2.7 381.3±35.3 9± 0.2 107.8± 2.1 −63.5±2.1 35◦C, wc LJP:nk Moretti et al., 2010
iPSC-CM V 72±1.2 314.4±17.6 26.8± 6.3 113.2± 2.4 −63.4±1.3 36◦C, pp LJP: nk Lahti et al., 2012
iPSC-CM V 35.5±2.1 414.7±21.8 27.8± 4.8 101.5± 2.5 −75.6±1.2 35–37◦C pp, LJP: nk Ma et al., 2011
iPSC-CM V 28±5 495±36 9.5± 1.8 109± 3 −57±1 32◦C, wc LJP: nk Itzhaki et al., 2011a
iPSC-CM* ns 60 173.5±12.2 115.7± 18.4 106± 3.2 −72.4±0.9 37◦C, pp LJP: corr Davis et al., 2012
hESC-CM V 47.1±23.3 247.2±66.7 13.2± 6.2 85.4± 9.3 −53.9±8.6 37◦C, me LJP: nk He et al., 2003
hESC-CM V 285.8±52.6 11.4± 2.8 86.8± 52.6 −62.3±8.6 rt, wc LJP: nk Zhang et al., 2011
VM* 50 213±7 215± 33 106.7± 1.4 −81.8±3.3 37◦C, wc LJP: nk Magyar et al., 2000
VM endo* 60 330±16 234± 28 105± 2 −87.1±1 37◦C, wc LJP: nk Drouin et al., 1998
VM epi* 60 351±14 228± 11 104± 2 −86±1 37◦C, wc LJP: nk Drouin et al., 1998
iPS-CM V, iPS-CM of ventricular-like phenotype; iPS-CM ns, not specified to action potential type; VM, native human ventricular myocyte; endo, endocardial; epi,
epicardial; BPM, beats per minute; APD90, action potential duration at 90% of repolarization; dV/dtmax, maximal upstroke velocity; APA, action potential amplitude;
MDP, maximum diastolic potential; RMP, resting membrane potential; *, non spontaneous beating cells; hESC-CM V, hESC-CM of ventricular-like phenotype; me,
micro electrode; wc, whole cell patch-clamp configuration; ljp: corr, corrected for liquid junction potential; ljp:nk, not known if corrected for liquid junction potential;
rt, room temperature.
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The duration of ventricular-like hiPSC-CM APs, for example at
90% of repolarization (APD90), is longer in spontaneous active
cells (313–495ms) compared to non-spontaneously active hiPSC-
CMs (173ms) and native freshly isolated CMs (213–351ms)
(Table 1). The AP amplitude (APA) for most ventricular-like
hiPSC-CM APs (87–113mV) is comparable to native ventricu-
lar CMs (104–106mV), which due to the depolarized MDP in
hiPSC-CM results in a higher overshoot of the hiPSC-CMAP. The
direct comparison between the APs is complicated by the differ-
ences in experimental techniques used. Most hiPSC-CM studies
used a temperature between 35 and 37◦C; only in the study of
Itzhaki was a temperature of 32◦C used. This could be a possi-
ble explanation of the depolarized MDP, slow dV/dtmax and long
APD90 in this latter study (Itzhaki et al., 2011a). The majority of
the studies used the ruptured whole-cell patch-clamp technique,
and three studies (Ma et al., 2011; Davis et al., 2012; Lahti et al.,
2012) used the perforated patch-clamp technique. In the latter
technique it is possible to perform experiments more close to
physiological conditions since cell dialysis is minimal and EGTA,
a buffer for Ca2+ ions, is absent.
MEMBRANE CURRENTS
The shape of the AP is the result of the various inwardly and
outwardly directed ion currents present in the CM. A schematic
overview of the different ionicmembrane currents underlying the
ventricular AP and their course is depicted in Figure 1. Because of
the clear differences in AP shape between native CMs and hiPSC-
CMs, one can assume that differences exist in the content and
function of the various cardiac ion channels between the two cell
types. Thus, before hiPSC-CMs can be used as a cell model in the
study of cardiac arrhythmia syndrome, it is important to carry out
a detailed comparison between the cardiac ion currents in hiPSC-
CMs with those in native CMs. In the description of the cardiac
ion currents below, a comparison between hiPSC-CMs displaying
ventricular-like APs and healthy native human ventricular CMs is
made, unless stated otherwise.
Sodium current
The cardiac Na+ current (INa) is responsible for the AP upstroke
in ventricular CMs [see (Berecki et al., 2010), and primary refer-
ences cited therein]. Mutations in the genes encoding the α- and
β-subunits of the cardiac Na+ channel can alter the kinetics and
availability of the cardiac Na+ current (Remme et al., 2008). As
stated before, the upstroke velocity in hiPSC-CMAPs is extremely
low compared to the AP upstroke of freshly isolated human ven-
tricular CMs. In hiPSC-CM, INa was studied in detail in two
reports (Ma et al., 2011; Davis et al., 2012). Ma et al. (2011)
report a half-maximal potential (V1/2) of activation and inactiva-
tion of –34.1 and –96.1mV, respectively. Davis et al. (2012) report
a V1/2 of activation of ∼42mV. The findings of these studies
are consistent with values reported for native human ventricular
CMs (Sakakibara et al., 1993) (Table 2). The low temperature and
FIGURE 1 | (A) Schematic representation of a human ventricular action
potential (top panel). Numbers denote the different phases of the ventricular
action potential. The dashed line represents phase 4 depolarization normally
present in cells from the conduction system and not in ventricular CMs.
Underlying ionic membrane currents and their schematic time course are
depicted below. (B) Schematic representation of an early afterdepolarization
(EAD) and its underlying mechanism. (C) Schematic representation of a
delayed afterdepolarization (DAD) and its underlying mechanism. INa, Na+
current; ICa,L, L-type Ca2+ current; ICa,T, T-type Ca2+ current; Ito1, transient
outward current type 1; ICl(Ca), Ca2+ activated Cl− current, also called Ito2;
IKur, ultra rapid component of the delayed rectifier K+ current, IKr, rapid
component of the delayed rectifier K+ current; IKs, slow component of the
delayed rectifier K+ current; IK1, inward rectifier K+ current; If, funny current;
INCX, Na+/Ca2+ exchange current.
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reduced Na+ concentration used to study the maximal peak INa
in native human ventricular CM (Sakakibara et al., 1993) prevents
comparison with the maximal peak INa measured in hiPSC-CM
(Ma et al., 2011; Davis et al., 2012). Other INa characteristics,
such as recovery from inactivation and slow inactivation have
not been reported to date. In the presence of the Na+ channel
blocker tetrodotoxin (TTX) the upstroke of the AP in hiPSC-
CMs is delayed and the dV/dtmax is reduced (Ma et al., 2011).
In hESC-derived CMs (hESC-CM) the Na+ channel blocker lido-
caine also reduced the spontaneous beating rate (Kuzmenkin
et al., 2009). Whether INa plays a role in spontaneous activity in
hiPSC-CM is unknown. However, hiPSC-CMs have prominent
Na+ currents with characteristics close to that of native human
ventricular CMs, despite any information to compare maximal
peak INa, it seems that the low dV/dtmax of spontaneously active
ventricular-like hiPSC-CM APs seems thus due to lower func-
tional availability of Na+ channels (related to the relative positive
value of the RMP) rather than differences in INa density.
Calcium current
Two types of Ca2+ current exist in the mammalian heart, i.e., the
L-type (ICa,L) and T-type (ICa,T) Ca2+ current [for review, see
(Nerbonne and Kass, 2005)]. Patch clamp studies have demon-
strated the presence of the ICa,L in hiPSC-CM with a V1/2
of activation and inactivation of –15 and –29mV, respectively
(Ma et al., 2011). These values are more comparable to those
found in native atrial CMs (–12 and –27mV, for V1/2 of acti-
vation and inactivation, respectively) (Mewes and Ravens, 1994)
than native ventricular myocytes (–4.2 and –4.7mV and –23.5
and –19.3mV) (Mewes and Ravens, 1994; Magyar et al., 2000).
The maximal peak ICa,L in hiPSC-CM reported by Ma et al.
(2011) is 16.4 pA/pF, which is much higher than the 3.3 pA/pF
reported in hiPSC-CM by Yazawa et al. (2011). In native ventric-
ular CMs the amplitudes of the maximal current density varies
between 2.2 and 10.2 pA/pF (Mewes and Ravens, 1994; Magyar
et al., 2000) The higher maximal peak ICa,L in the study of Ma
et al. (2011) may be explained by the higher extracellular Ca2+
and higher temperatures used in their experiments. Blocking of
the ICa,L with nifedipine results in shortening of the AP dura-
tion and field potential duration (FDP) with minimal effects on
dV/dtmax (Itzhaki et al., 2011a; Ma et al., 2011). Long-term appli-
cation of nifedipine resulted in cessation of beating in some EBs
(Itzhaki et al., 2011a).
Functional presence of the ICa,T has not been reported in
hiPSC-CM. Ma et al. (2011) did not find clear evidence for its
presence. ICa,T is present in the human heart conduction system,
where it plays a role in facilitation of pacemaker depolarization,
but is not functionally present in healthy human native ventric-
ular CMs (Ono and Iijima, 2010). The T-type Ca2+ channels
are re-expressed in atrial and ventricular CMs under patholog-
ical conditions such as cardiac hypertrophy and heart failure
(Ono and Iijima, 2010).
Transient outward current
Two transient outward current components are found in native
mammalian cardiac cells, one carried by K+(Ito1), the other by
Cl− ions (Ito2) [for review, see (Nerbonne and Kass, 2005)].
While it is not yet known whether Ito2 is present in hiPSC-CMs,
native human ventricular CMs are known to lack Ito2 (Verkerk
et al., 2001). On the otherhand, Ito1 has been found in hiPSC-
CMs (Moretti et al., 2010; Ma et al., 2011), but data about gating
properties are not known. Reported peak current densities of
Ito1 in hiPSC-CM display large variation, namely between 2.4
(Ma et al., 2011) and 30 pA/pF (Moretti et al., 2010), both at
60mV. Values reported for native ventricular CMs vary between
2.3 and 16 pA/pF (Wettwer et al., 1994; Nabäuer et al., 1996).
Although an exact comparison of Ito1 density between hiPSC-CM
and native human CMs is hampered by differences in experimen-
tal conditions, Ito1 current density also depends on the site from
which the native ventricular CMs are isolated, with larger current
densities reported in human subepicardial ventricular myocytes
compared to endocardial ventricular CMs (Beuckelmann et al.,
1993; Wettwer et al., 1994).
Studies of Ito1 block on hiPSC-CM APs have not yet been
performed. However, due to the depolarized MDP values in
hiPSC-CM, Ito1 function may be limited because most channels
will be inactivated (Varro and Papp, 1992). Further studies are
required to address the function of Ito1 in hiPSC-CM in detail.
The delayed rectifier potassium current
In the mammalian heart, the delayed rectifier K+ current (IK) is
composed of three different components: the ultrarapid (IKur),
the rapid (IKr), and the slow (IKs) components [for review,
see (Nerbonne and Kass, 2005)]. To our knowledge, studies to
elucidate the presence and function of IKur in hiPSC-CMs are
lacking.
IKr has been reported in hiPSC-CM with a maximal IKr den-
sity varying between 0.55 and 1.9 pA/pF (Moretti et al., 2010;
Itzhaki et al., 2011a; Ma et al., 2011; Lahti et al., 2012), values
comparable to those in native human CMs where IKr densities
are between 0.25 and 0.6 pA/pF (Iost et al., 1998; Magyar et al.,
2000; Jost et al., 2009). V1/2 of activation is –22.7mV (Ma et al.,
2011) in hiPSC-CMand –5.74mV in native ventricular CMs (Iost
et al., 1998) and –14mV in atrial CMs (Wang et al., 1994). In
hiPSC-CMs, blockade of IKr by E4031 resulted in a significant
AP prolongation In addition, E4031 induced early afterdepolar-
izations (EADs) (Itzhaki et al., 2011a; Ma et al., 2011; Matsa et al.,
2011; Lahti et al., 2012), that is afterdepolarization during the AP
(Figure 1B) due to the reactivation of ICa,L (Verkerk et al., 2000b).
Thus, IKr plays a prominent role in the repolarization phase of
hiPSC-CM APs. Interestingly, in hESC-CM E4031 reduced the
beating rate (Kuzmenkin et al., 2009) suggesting that IKr also plays
a role in spontaneous activity.
The presence of IKs in hiPSC-CMs has been reported in two
studies. Ma et al. (2011) found IKs in 5 out of 16 cells stud-
ied, and when present the average IKs density was 0.31 pA/pF. In
contrast, Moretti et al. (2010) measured IKs in all studied cells
and the average density was around 2.5 pA/pF [estimated from
Figure 4A (Moretti et al., 2010)]. In native left ventricular human
CMs, Virag et al. (2001) identified IKs in 31 out of 58 cells and
the maximal current density was approximately 0.18 pA/pF. In
hiPSC-CMs, blockade of IKs by chromanol 293B results only in
minimal prolongation of the AP (Ma et al., 2011). This is con-
sistent with the relative small number of cells exhibiting IKs and
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the small IKs densities found in their study, but contrast with
the effects of a loss-of-function IKs mutation which results in a
prominent AP prolongation (see paragraph “LQT1”). A study by
Wang et al. (2011) in hESC-CMs suggests altered expression of
the β-subunit mink encoded by the KCNE1 gene, as a mechanism
for variable IKs function in the developing heart and in disease.
Inward rectifier current
In atrial and ventricular CMs, the inward rectifier K+ current
(IK1) is an important contributor to the maintenance of the
RMP and contributes to the terminal phase of repolarization
(Dhamoon and Jalife, 2005). IK1 was found to be present in
hiPSC-CM (Ma et al., 2011). IK1 density in hiPSC-CM is four
times smaller than that reported in native ventricular CMs, 0.9
(Ma et al., 2011) and 3.6 pA/pF (Magyar et al., 2000), respectively.
In hESC-CMs IK1 is significantly increased in longer cultured
hiPSC-CMs, these cells also displayed a flattened diastolic depo-
larization rate and decreased spontaneous activity (Sartiani et al.,
2007).
The small IK1 densities in hiPSC-CMs may explain the fre-
quently observed spontaneous activity in these cells. However,
whether all hiPSC-CMs have a low IK1 density or whether a bias
is introduced by the selection of spontaneously active cells for
patch-clamp needs to be elucidated.
The acetylcholine-activated K+ current
The acetylcholine-activated K+ current (IK,ACh) is involved in
parasympathetic regulation of heart rate (Tamargo et al., 2004).
IK,ACh is to our knowledge not yet studied in hiPSC-CM. Studies
addressing the presence of IK,ACh in hiPSC-CM might be partic-
ularly important in modeling atrial arrhythmias, as blockers of
IK,Ach, which leave ventricular repolarization intact, are effective
in the treatment of atrial fibrillation (Hashimoto et al., 2006).
The ATP-sensitive K+ current
The ATP-sensitive K+ current (IK,ATP) has not been studied in
detail in hiPSC-CMs. However, the IK,ATP channel openers nico-
randil and pinacidil shorten the AP in hiPSC-CMs (Itzhaki et al.,
2011a; Matsa et al., 2011), suggesting that IK,ATP channels are
present in these cells. Further studies are required to address the
presence and function of IK,ATP in hiPSC-CM in detail.
The hyperpolarization-activated “funny” current
The funny current (If) is an inward current activating at hyper-
polarized membrane potentials [for review, see (Verkerk et al.,
2007)]. In human sinoatrial node cells, the current density of If
at a membrane potential of –130mV is reported to be 8 pA/pF
(Verkerk et al., 2007). If is also described in human atrial CMs
(El Chemaly et al., 2007) and in human ventricular CMs dur-
ing heart failure [(Hoppe et al., 1998)]. The current densities
reported, however, are much smaller, compared to human sinoa-
trial node cells. hiPSC-CMs also exhibit If (Ma et al., 2011) and
the reported current density is 4.1 pA/pF (Ma et al., 2011). The
relatively high If density in hiPSC-CMs compared to human ven-
tricular CMsmight be attributed to the fact that these cells express
higher levels of the HCN isoforms (HCN1, 2, 4) as compared to
adult human CMs. (Synnergren et al., 2012). In hiPSC-CMs, If
starts to activate at potentials negative of –60mV and has a V1/2
of activation of –84mV (Ma et al., 2011) and may therefore have
a role in spontaneous activity in these cells. hESC-CMs have com-
parable characteristics of If, and in these cells blockade of If with
zatebradine resulted in slowing of spontaneous activity due to a
reduced diastolic depolarization rate (Sartiani et al., 2007).
Na+-Ca2+ exchange current
The Na+-Ca2+ exchange current (INCX) is crucial for Ca2+ extru-
sion from the cell and plays a role in the electric activity of
mammalian CMs (Sipido et al., 2007). While the functional prop-
erties of INCX have not been studied in hiPSC-CM, the presence
of the Na+-Ca2+ exchanger in hiPSC-CMhas been demonstrated
at the level of the protein (Lee et al., 2011). INCX is present in
hESC-CM and its density increases with maturation (Fu et al.,
2010).
In human CMs, Ca2+ extrusion by the Na+/Ca2+ exchanger
is the major mechanism to balance the Ca2+ influx through the
ICa,L (Sipido et al., 2007). In addition, the Na+/Ca2+ exchanger
has a function during depolarization where it contributes in its
reverse mode (Ca2+ influx) to the total amount of Ca2+ influx.
The amplitude of the INCX depends on the membrane potential
and the intracellular levels of Na+ ([Na+]i) and Ca+ ([Ca2+]i)
(Sipido et al., 2007). Altered [Na+]i and/or [Ca2+]i will lead to
altered INCX and can cause cardiac arrhythmias due to sponta-
neous Ca2+ releases from the SR. Studying the INCX in hiPSC-CM
might be of particular interest in cardiac arrhythmia models of
CPVT and LQT3. CPVT is associated with mutations in the RyR2
which can lead to increased [Ca2+]i due to altered gating proper-
ties of the RyR2 receptor. In LQT3 syndrome there is an increased
persistent INa (Remme et al., 2006), which might lead to elevated
levels of [Na+]i.
EXCITATION-CONTRACTIONCOUPLING
hiPSC-CMs display clearly visible contractions. In native adult
CMs, a small influx of Ca2+ through the L-type Ca2+ chan-
nels triggers a several-fold multiplied Ca2+ release from the
sarcoplasmic reticulum (SR) via ryanodine receptors (RyRs).
This phenomenon is referred to as “Ca2+−induced Ca2+ release”
(CICR) (Lee et al., 2011). CICR is the key mechanism underlying
excitation-contraction coupling. The key Ca2+ handling proteins,
RyR2, SR Ca2+-ATPase (SERCA), junctin (Jun), triadin (TRDN),
Na+/Ca2+ exchanger (NCX), calsequestrin (CASQ2), L-type
Ca2+ channel (Cav1.2), inositol-1,4,5-trisphosphate receptor
(IP3R2) and PLN are expressed in hiPSC-CM (Itzhaki et al.,
2011b; Lee et al., 2011). Spontaneous rhythmic Ca2+ transients
are present in hiPSC-CM, and blocking of the ICa,L by nifedip-
ine, abolishes Ca2+ transients (Itzhaki et al., 2011b). The presence
of functional SR and RyRs was proven by application of caffeine,
which induced a large Ca2+ transient (Itzhaki et al., 2011b; Lee
et al., 2011), consistent with findings in human ventricular CMs
(Piacentino et al., 2003). In addition, ryanodine caused a reduc-
tion in the amplitude of the Ca2+ transient (Itzhaki et al., 2011b;
Lee et al., 2011). The pattern of Ca2+ transient in hiPSC-CM was
studied by transverse line-scan images and revealed a U-shape
Ca2+ wavefront (the rise of Ca2+ in the periphery is faster than in
the center of the cell), which is typical for t-tubule deficient cells
(Lee et al., 2011). This suggests that hiPSC-CMs lack t-tubuli, an
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observation which is in line with that of Novak and co-workers
(Novak et al., 2012) who did not find t-tubuli with transmission
electron microscopy. This would mean that hiPSC-CMs likely
have poor coupling between Ca2+ influx through L-type Ca2+
channels and Ca2+ release from the SR through RyRs.
HUMAN iPSC-CMMODELS FOR INHERITED CARDIAC
ARRHYTHMIAS
hiPSC-CMMODELS FOR LQTS
LQT1
Moretti and co-workers (Moretti et al., 2010) were the first to
publish on a hiPSC-CM model for a primarily electrical dis-
ease, namely LQT1. LQT1 is a repolarization disorder identified
by a prolongation of the QT interval on the ECG due to muta-
tions in the KCNQ1 gene, encoding the α subunit of the K+
channel responsible of IKs (Wilde and Bezzina, 2005). They
investigators obtained fibroblasts from two, so far, asymptomatic
patients, with the KCNQ1-G569A mutation and two healthy con-
trols (Moretti et al., 2010). These fibroblasts were infected with
retroviruses encoding OCT3/4, SOX2, KLF4, and c-MYC; hiPSC-
CMs were differentiated as EBs. In this study AP characteristics
and K+ currents were investigated in spontaneously beating cells.
Three different types of AP s were distinguished, that were desig-
nated as ventricular-, atrial-, and nodal-like. These investigators
also correlated these characteristics with gene-expression anal-
ysis of specific myocyte-lineage markers (MLC2v, MLC2a, and
HCN4 for ventricular-, atrial- and nodal-like cells, respectively).
The delayed rectifier currents were studied in ventricular-like
myocytes. In hiPSC-CMs derived from the LQT1 patient (LQT1-
iPSC-CM), IKs peak and tail current densities were reduced
by approximately 75%, and IKr conductance was unaffected.
APs of atrial-like and ventricular-like hiPSC-CMs were signifi-
cantly prolonged in LQT1-iPSC-CMs compared to control (WT-
iPSC-CMs). Adaptation of the AP duration to higher pacing
frequencies and the response to isoproterenol were impaired in
LQT- iPSC-CM. EADs were elicited in response to isoproterenol
(a β-adrenergic agonist) in 6 out of 9 LQT1-iPSC-CM and never
in WT-iPSC-CM. When propranolol (a non-selective β-blocker)
was applied the effect of isoproterenol was blunted. These data
are in line with observations in LQT1 patients as these patients
suffer from arrhythmias during increased heart rates caused by
emotional stress or exercise.  The data is also in line with the ben-
eficial effects of β-blockers in suppressing arrythmias in these
patients (Ruan et al., 2008). Immunocytochemistry revealed that
the KCNQ1-G569A mutation leads to impaired trafficking and
localization of the mutant channels.
LQT2
Three groups have published on hiPSC-CM models of LQT2
(Itzhaki et al., 2011a,b; Matsa et al., 2011; Lahti et al., 2012).
LQT2 is a repolarization disorder caused bymutations inKCNH2,
encoding IKr channels (Wilde and Bezzina, 2005).
Itzhaki et al. (2011a) reported on a hiPSC-CMs model gen-
erated from dermal fibroblasts obtained from a 28-year-old
woman with a diagnosis of familial LQT2 due to the KCNH2-
A614V mutation. Clinical data of the patient were not shown.
Fibroblasts were reprogrammed by retroviral infection with
vectors encoding for SOX-2, KLF4, and OCT4. In this study
EB formation was used for differentiation of the hiPSC into
CMs. In this study APs were measured from spontaneously con-
tracting clusters and the hiPSC-CMs were classified as nodal-,
atrial-, and ventricular-like. Prolongation of repolarization and
predisposition to the development of EADs was shown in cells
with atrial- and ventricular-like APs. For voltage clamp exper-
iments the spontaneously beating clusters were dissociated to
single cells. Peak amplitudes of IKr were found to be signifi-
cantly smaller in LQT2-iPSC-CM compared to WT-iPSC-CM.
FDP corrected for variations in beating frequency were longer
in LQT2-iPSC-CM compared to WT-iPSC-CM. When IKr was
blocked by the hERG blocker E4021, the AP prolonged and
EADs were seen in 66% of the cells studied. Furthermore, the
effects of agents that may have a therapeutic effect in preventing
arrhythmias were also studied. These agents include nifedipine,
pinacidil, and ryanodine. Because Ca2+ influx through L-type
Ca2+ channels contributes to AP duration and has a role in EAD
formation, inhibition of ICa,L by nifedipine was proposed to be
anti-arrhythmic. Another anti-arrhythmic strategy proposed was
to augment the repolarization currents, by the IK,ATP channel
opener pinacidil. Both interventions resulted in AP shortening
and abolished propensity to EADs. This study also demonstrated
that ranolazine, a blocker of the persistent INa, did not shorten the
AP duration, but prevented EADs.
Matsa et al. (2011) generated hiPSC-CMs of a symptomatic
and an asymptomatic carrier of the G1681A mutation in KCNH2.
The symptomatic patient, female with a QTc interval of up to
571ms, experienced 11 episodes of syncope in 12 months. As
is typical for LQT2, episodes occurred at arousal from sleep
and not during competitive sports. Her mother was the asymp-
tomatic individual studied; although her QTc-interval was pro-
longed she had not experienced any symptoms. The hiPSC-CMs
were derived from punch biopsies of skin, which were repro-
grammed by lentiviral delivery of OCT4, SOX2 NANOG, and
LIN28; EB formation was used for differentiation of cells into
CMs. IKr current characteristics were not studied. The derived
hiPSC-CMs showed APs which were categorized as ventricular-,
atrial- and pacemaker-like. Ventricular- and atrial-like APs from
the symotomatic patient and her mother showed increased dura-
tions compared to APs of the genetically unrelated control; AP
duration was less in the maternal hiPSC-CMs compared to those
of the patient. Application of isoprenaline resulted in 25% of
LQT2-iPSC-CMs in electrophysiological abnormalities, includ-
ing EADs. Isoprenaline-induced arrhythmias were ameliorated by
nadolol or propanolol, non-selective β-blockers. This is in line
with the clinical picture in LQT2 as these patients experience
arrhythmias due to increased heart rates caused by emotional and
similar stress, mainly auditory stimulation and arousal from sleep.
As for LQT1, LQT2 patients are often treated with β-blockers
for prevention of cardiac events (Ruan et al., 2008). IKr block-
ade by E4031 resulted in prolongation of the AP duration and
EADs in 30% of the LQT2-iPSC-CMs, but never in control cells.
Nicorandil, an IK,ATP channel opener, and PD-118057, an IKr
channel enhancer, shortened the AP in LQT2-iPSC-CM, showing
that potassium channel activators can normalize the prolonged
repolarization in LQT2.
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Lahti et al. (2012) derived hiPSC-CMs from an asymptomatic
carrier of the R176W mutation in the KCNH2. This mutation is
one of the four founder mutations of LQTS cases in Finland, and
present in one in 400 Finns (Marjamaa et al., 2009). The QTc
intervals of patients carrying the R176W mutation range from
386 to 569ms, with a mean of 448ms (Fodstad et al., 2006). In
the study of Lahti et al. (2012), fibroblasts were infected with
lentivirus followed by retroviruses encoding for OCT4, SOX2,
KLF4, and MYC to generate iPSC-CMs. CM differentiation was
achieved by co-culturing hiPSC with END-2 cells. APs were
divided into two types, atrial- and ventricular-like APs. Only
the ventricular-like APs showed significantly increased APD90.
The AP frequency had a tendency toward slower frequencies in
LQT2-iPSC-CM. EADs were present in 1 of 20 LQT2 iPSC-CMs
and were never observed in WT-iPSC-CMs. IKr step and tail
current densities were reduced by 40–46%. The APs of LQT2-
iPSC-CMs had a significantly prolonged duration compared to
WT AP, especially at low frequencies. The IKr blocker E4031
provoked EADs in WT-iPSC-CM and LQT2-iPSC-CM, with the
effect on LQT2-iPSC-CMs being more pronounced. Sotalol, a
non-selective β-blocker elicited EADs only in LQT2-iPSC-CM.
These three studies on LQT2 show that LQT-iPSC-CMs of
symptomatic patients show amore severe cellular phenotype than
those obtained from asymptomatic patients with the same muta-
tion. However, assessing severity in the hiPSC-CMs system is
challenging. For instance, blocking IKr by E-4031 in WT-iPSC-
CMs leads to different findings in different studies. In the study
of Matsa et al. (2011) no EADs were provoked by the application
of E4031, whereas in the study of Ma et al. (2011) and Lahti et al.
(2012) EADs could be provoked in >50% of WT-iPSC-CM. This
might reflect diversity of hiPSC-CM lines. However, the differ-
ences between the outcomes of these studies might also be caused
by the use of different concentrations E-4031. Ma et al. (2011)
and Lahti et al. (2012) used a concentration of 100 nmol/l and
500 nmol/l, respectively. The concentration used by Matsa et al.
(2011) is not known.
LQT3/Conduction disease/BrS
LQT3 is a repolarization disorder caused by gain-of-function
mutations in SCN5A encoding the cardiac Na+ channel. These
mutations cause an increased persistent Na+ current which acts
to prolong CM repolarization and increase AP duration (Wilde
and Bezzina, 2005). On the otherhand, SCN5A mutations associ-
ated with loss of channel function cause conduction disease and
Brugada Syndrome (BrS). The latter is an arrhythmia syndrome
characterized by ST segment elevation in the right precordial
leads of the EGC; SCN5A mutations account for around 20% of
BrS cases (Wilde and Bezzina, 2005). Loss of Na+ channel func-
tion leads to a decreased peak INa, which causes slowing of the
upstroke velocity of the AP.
Recently, we have, generated an iPSC-CM model of a patient
carrying the SCN5A-1795insD mutation (Davis et al., 2012). This
mutation gives rise to a phenotype of LQT3 as well as BrS and
conduction defects, caused by both gain- and loss-of-function
effects on the cardiac Na+ channel, respectively (Remme et al.,
2006, 2009). In this study we generated hiPSC-CMs by trans-
ducing fibroblasts with lentiviral vectors encoding OCT4, SOX2,
KLF4 and C-MYC (Davis et al., 2012). Cardiac differentiation
was induced by co-culture with END-2 cells. In line with the
known effects of the mutation in a knock-in mouse model, and
in line with the clinical presentation in mutation carriers, we
observed a decrease in peak INa and an increase in persistent INa in
the hiPSC-CMs with SCN5A-1795insD compared to genetically
unrelated control. APs measured in non-spontaneously active
hiPSC-CMs displayed a reduced upstroke velocity and a pro-
longed duration compared to those derived from a genetically
unrelated control.
LQT8/Timothy syndrome
LQT8 and Timothy syndrome are caused by mutation in
the CACNA1C gene encoding the L-type Ca2+ channel.
Repolarization disease is only one facet of LQT8 as CACNA1C
mutations also give rise to other features including syndactyly,
heart malformations, and autism spectrum disorders (Yazawa
et al., 2011). Yazawa et al. (2011) studied hiPSC-CMs of
two patients with LQT8. Fibroblasts were isolated from skin
biopsies and were reprogrammed using four retroviruses con-
taining SOX2, OCT3/4, KLF4, and MYC. EBs were used in
the generation of hiPSC-CMs. EBs from LQT8/Timothy syn-
drome hiPSC lines contracted at 30 bpm, whereas control
hiPSC-line EBs contracted at a rate of 60 bpm. The LQT8-
iPSC-CM showed delay in inactivation of ICa,L and abnormal-
ities in intracellular Ca2+ handling, with larger and prolonged
Ca2+ transients. Importantly, such aspects of ICa,L mutations
can not be revealed when studying the mutation in a het-
erologous cell system. The APs of LQT8/Timothy syndrome
ventricular-like hiPSC-CMs were three times longer than those
of WT hiPSC-CMs. Roscovitine, a compound that increases
the voltage-dependent inactivation of the voltage dependent
Ca2+ channel, reverted the delayed inactivation and restored the
irregular Ca2+ transients associated with LQT8/Timothy syn-
drome.
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR
TACHYCARDIA
CPVT is characterized by cateholamine/stress-induced ventricu-
lar arrhythmias that can lead to sudden cardiac death in young
individuals (Priori and Chen, 2011). CPVT is linked to muta-
tions in the RYR2 gene, encoding an intracellular Ca2+ release
channel, and mutations in CASQ2, encoding a calcium binding
protein in the SR which stores Ca2. RyR2 andCASQ2 play a role in
Ca2+ cycling and contractile activity of the CM (Priori and Chen,
2011). To date, three groups have published a CPVT hiPSCmodel
(Fatima et al., 2011; Jung et al., 2012; Novak et al., 2012).
Fatima et al. (2011) studied the F243I mutation in the RYR2
gene. A skin biopsy of a patient with CPVT carrying the F243I
mutation in theRYR2 gene was taken and fibroblasts derived from
this biopsy were infected with retroviruses encoding OCT3/4.
SOX2, KLF4, and c-MYC. Cardiac differentiation was achieved
by co-culturing with END-2 cells. APs were measured in spon-
taneously beating single hiPSC-CMs and were categorized as
ventricular-, atrial-, and nodal-like APs. Isoproterenol was used
to evoke the phenotype. In 22 out of 38 CPVT-iPSC-CMs isopre-
naline resulted in a negative chronotropic response and 13 cells
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exhibited delayed afterdepolarizations (DADs), which are after-
depolarizations after and AP (Figure 1C) due to spontaneous SR
Ca2+ release what activates INCX (Verkerk et al., 2000a). All con-
trol hiPSC-CM showed normal positive chronotropic response.
Confocal fluorescence imaging revealed spontaneous local Ca2+
release events of higher amplitude and longer duration in CPVT-
iPS-CMs. In addition, the CPVT-iPSC-CMs showed a decrease in
ICa,L and Ca2+ transients in the presence of forskolin, an adenyl
cyclase activator. As the authors state, this is likely due to the large
and sustained rise of intracellular Ca2+ concentration.
Jung et al. (2012) studied the RYR2 mutation S406L.
Fibroblasts of the patient were transduced with a retroviral vec-
tor encoding SOX2, OCT4, KLF4, and c-MYC. To direct the
hiPSCs to the cardiac lineage, EB differentiation was used. The
CPVT-iPSC-CMshowed elevated Ca2+ concentrations, a reduced
SR Ca2+ content, and increased susceptibility to DADs under
catecholaminergic stress induced by isoproterenol. Further the
authors investigated the ability of dantrolene to rescue the dis-
ease phenotype. Dantrolene is a hydrantoin derivative and mus-
cle relaxant, currently used as therapy in cases with malignant
hyperthermia, a disorder caused by mutations in the skeletal
ryanodine receptor (RYR1) (Kobayashi et al., 2009). Dantrolene,
restored normal Ca2+ spark properties and the arrhythmogenic
phenotype.
Novak et al. (2012) studied the effect of the autosomal
recessive missense mutation D307H in the CASQ2 gene. Dermal
fibroblasts of two mutation carriers were transduced with a
single lentiviral vector containing OCT4, SOX2, KLF4, and
c-MYC. Differentiation toward hiPSC-CMs was achieved by EB
formation. Spontaneous beating rate of differentiated EBs was
significantly lower in CPVT-iPSC-CMs (∼26 bpm) compared
to control iPSC-CMs (∼39 bpm). Isoproterenol induced DADs,
oscillatory arrhythmic prepotentials (diastolic voltage oscillation,
which appear during the late diastolic depolarization) and
increased [Ca2+]i.
CONCLUSIONS AND FUTURE PERSPECTIVES
The hiPSC-CM models described in this review show that it
is possible to recapitulate in vitro in the hiPSC-CM system the
disease phenotype of patients with Mendelian cardiac rhythm
disorders. Furthermore, different studies have shown that LQT-
iPSC-CMs of symptomatic patients show a more severe cellular
phenotype than those obtained from asymptomatic patients with
the same mutation (Itzhaki et al., 2011a; Matsa et al., 2011; Lahti
et al., 2012). Moreover, hiPSC-CMs can recapitulate a pheno-
type that cannot be shown in a heterologous expression system
(Lahti et al., 2012). For example, Lahti et al. (2012) reported
a decrease of ∼43% in IKr density in LQT2- iPSC-CMs with
the R176W mutation, which was not revealed in a heterologous
expression system. This might reflect, amongst others, differ-
ences in cellular environment between the two cell systems or
may be due to the effect of high transgene expression as a con-
sequence of the use of a strong promoter in the heterologous
expression system. A significant advantage of the hiPSC-CM sys-
tem is that in this system, in contrast to heterologous expression
systems, it also possible to study the effects on the AP and Ca2+
cycling.
The responses to some pharmacological agents are studied in
hiPSC-CMs. The results are in line with what is seen in patients,
healthy human beings, and adult CM. For example β-adrenergic
stimulation with isoproterenol leads to a positive chronotropic
effect and AP shorterning (Zhang et al., 2009; Moretti et al., 2010)
and application of β-blockers blunt the effect of isoproterenol
(Moretti et al., 2010). Also the AP shortening effects of IK,ATP
openers pinacidil and nicorandil and the ICa channel blocker
nifedipine was captured in hiPSC-CM.
Functional INa (Ma et al., 2011; Davis et al., 2012),
ICa,L(Itzhaki et al., 2011a; Ma et al., 2011; Yazawa et al., 2011),
IKr (Itzhaki et al., 2011a; Ma et al., 2011; Matsa et al., 2011; Lahti
et al., 2012) and IKs(Ma et al., 2011) have been demonstrated
in hIPSC-CMs and mutations affecting these channels as well as
pharmacological ion channel blockade were shown to impact on
the AP. While the functional presence of SR, RyRs and the Ca2+
binding protein CASQ2was demonstrated (Itzhaki et al., 2011b;
Lee et al., 2011; Novak et al., 2012), studies have shown that the
coupling between Ca2+ influx through L-type Ca2+ channels and
Ca2+ release from the SR through RyRs is poor as a consequence
of the lack of t-tubuli in hiPSC-CMS. Thus, the use of hiPSC-CMs
to study certain cardiac arrhythmia syndromes, such as CPVT
and LQT8, caused by mutations in one of the Ca2+ handling
proteins is limited to the study of the biophysical properties of
the affected protein. While Ito1, IK1, and If are present in hiPSC-
CMs (Ma et al., 2011), their contribution to electrical activity in
these cells has not been proven by pharmacological blockade or
through the effect of mutations in the respective genes. Openers
of IK,ATP shorten the AP (Itzhaki et al., 2011a; Matsa et al., 2011),
so functional presence can be presumed but needs to be studied
in more detail. The presence of INCX is also not studied in detail
but its functional presence can also be presumed since intact Ca2+
handling has been demonstrated (Itzhaki et al., 2011b; Lee et al.,
2011). Up till now there is no evidence for the functional presence
or absence of IK,ACh.
A difficulty in the use of hiPSC-CM models is their immature
electrophysiological phenotype, with depolarized MDP or RMP
and slow AP upstroke velocities compared to native CMs. The
MDP and upstroke velocity of hiPSC-CMs resemble more those
of fetal CMs than adult CMs (Davis et al., 2011). Furthermore,
most studies report that hiPSC-CM beat spontaneously, which
is also characteristic of fetal CMs (Mummery et al., 2003).
Of note, in our study on quiescent hiPSC-CMs we recorded a
more-negative RMP and a faster AP upstroke velocity (Davis
et al., 2012). Considering the importance of IK1 for setting the
RMP, it is likely that the quiescent hiPSC-CMs have a larger
IK1 than spontaneously beating hiPSC-CMs. It is not known
whether quiescent cells were also present among the hiPSC-CM
generated in studies in which spontaneously beating hiPSC-CMs
were studied. Possibly, in these studies, the spontaneous activity
was used as a tool to recognize CMs. A further consideration is
that cultured adult CMs show a depolarized MDP and slower AP
upstroke velocity compared to freshly isolated adult CMs. The
depolarized MDP in cultured CMs is known to be caused by
progressive decline in IK1 (Mitcheson et al., 1998). Another sim-
ilarity between cultured ventricular myocytes and hiPSC-CMs is
that different AP phenotypes are observed. In many hiPSC-CM
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studies different AP characteristics are observed and are classi-
fied as ventricular-like, atrial-like and nodal-like AP. Similarly,
when ventricular CMs are cultured different AP phenotypes are
observed after one day in culture, and more pronounced vari-
ability is evident after four days in culture (Mitcheson et al.,
1998).
Another difficulty is the purity of the population of hiPSC-
CMs acquired. With the current techniques it is not possible to
acquire a pure population of CMs, the fraction of CMs obtained
may vary from 1% to ∼50% of the total cells (Dambrot et al.,
2011). Moreover, as discussed above, the CMs that are generated
are in fact a mixed population of CMs displaying different AP
characteristics. One way in which this issue might be addressed
is through the use of selectable markers driven by CM lineage-
specific promoter elements. However, while this might be useful
in selecting CMs as opposed to other cell types, more research
is still required for the identification of promoter elements that
may be used in selecting for specific CM types (e.g., ventricu-
lar versus atrial). Another solution might be found in chemical
enhancement of cardiac differentiation. For instance, ascorbic
acid enhances cardiac differentiation and minimizes the interline
variance and facilitates the structural and functional maturation
of hiPSC-CMs (Cao et al., 2012). From hESC-CM research we
know that bone morphogenetic protein (BMP) signaling inhibi-
tion after mesodermal formation facilitates cardiac development.
In this study, also a possibility for ventricular or atrial specific dif-
ferentiation is shown (Zhang et al., 2011). Inhibition of retinoid
(RA) signaling by noggin leads to CM specification into ven-
tricular cells, whereas RA treatment leads to atrial specification
(Zhang et al., 2011). Direction of differentiation to nodal like
CMs can be achieved by activation of the Ca2+ activated potas-
sium channels of small and intermediate conductance (SKCas)
by 1-ethyl-2-benzimidazolinone (Kleger et al., 2010). Ventricular
specification and electrophysiological maturation of hESC-CMs
may also be promoted by microRNAs (miRs). MiR-499 was
shown to promote ventricular specification; miR-1 facilitates
electrophysiological maturation (Fu et al., 2011).
In summary, iPSC-CM models recapitulate the phenotype of
patients with cardiac arrhythmia syndromes. However, the inter-
pretation of electrophysiological data derived from these cells,
should be done with caution, since hiPSC-CMs present immature
phenotypes and do not recapitulate all the electrical characteris-
tics of an adult CM. Thus, studies addressing the maturity and
purity of the hiPSC-CMs acquired are needed, as well as stud-
ies to characterize the electrophysiological and pharmacological
characteristcs in more detail. Because of this, there are still lim-
itations for the use of this model system in studies on cardiac
rhythm disorders, especially if the disease causing mutation is not
known. So far, hiPSC-CMs have only been applied as models to
the study of disorders for which mutations in particular genes
have been identified. Future studies are likely to demonstrate the
potential of these cell systems in pointing us to pathophysiologi-
cal mechanisms for those cases for which no gene mutations are
yet known. Another future application of hiPSC-CMs is the use in
cardiac safety pharmacology and the development of new drugs.
hiPSC-CMs provide researchers with CMs of human origin which
are better-suited than CMs of animal origin or heterologous cell
systems. Furthermore, hiPSC-CMs provide us with the oppor-
tunity to test drugs in disease-specific CMs instead of healthy
CMs. Thus, in future studying hiPSC models might lead to novel
insights in pathophysiology, improve understanding of genotype-
phenotype relationships and could be used in the development
and testing of pharmacological agents to treat human cardiac
disease.
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